| 1 |
1,3-bis(2-chloroethyl)-1-nitrosourea
(845 times)
|
Neoplasms
(334 times)
|
MGMT (36 times)
CCNU (31 times)
BSO (29 times)
|
1965 IN VIVO ANTIVIRAL ACTIVITY OF 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA.
|
| 2 |
BACKGROUND: Carmustine
(4 times)
|
Magnetic Resonance Imaging
(1 time)
|
ep-MRI (1 time)
ep-T2-HIAs (1 time)
HGG (1 time)
|
1990 Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
|
| 3 |
biodegradable carmustine
(4 times)
|
Neoplasms
(2 times)
|
IL-12 (1 time)
KPS (1 time)
MRI (1 time)
|
2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
|
| 4 |
bis-chloroethyl-nitrosurea, carmustine
(3 times)
|
Neoplasms
(1 time)
|
LEFCT-EC (1 time)
|
2005 Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
|
| 5 |
Bacterial controlled nursing units
(2 times)
|
General Surgery
(1 time)
|
---
|
1977 The contribution of a bacterially isolated environment to the prevention of infection in seriously burned patients.
|
| 6 |
beam radiotherapy, and carmustine
(2 times)
|
Radiotherapy
(1 time)
|
ASTRO (1 time)
ESTRO (1 time)
|
2002 The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
|
| 7 |
bifunctional alkylators, including carmustine
(2 times)
|
Molecular Biology
(1 time)
|
MMR (2 times)
TMZ (2 times)
Mel (1 time)
|
2008 Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
|
| 8 |
both carmustine
(2 times)
|
Neoplasms
(2 times)
|
CPA (1 time)
GST (1 time)
LD10 (1 time)
|
1989 Toxicity of intraperitoneally administered antitumour drugs in athymic rats.
|
| 9 |
caused by carmustine
(2 times)
|
Neoplasms
(1 time)
|
i.p (1 time)
MDA (1 time)
TMZ (1 time)
|
1988 Cell-cycle, phase-specific cell killing by carmustine in sensitive and resistant cells.
|
| 10 |
N-nitroso-1,3-bis-(2-chloroethyl)urea
(2 times)
|
General Surgery
(2 times)
|
---
|
1984 [Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperthermia].
|
| 11 |
BACKGROUND: Intra-arterial chemotherapy with carmustine
(1 time)
|
Neoplasms
(1 time)
|
BTCG (1 time)
CT (1 time)
|
1995 Evaluating glioma therapies: modeling treatments and predicting outcomes.
|
| 12 |
BACKGROUND: Local delivery of carmustine
(1 time)
|
Neoplasms
(1 time)
|
DOX (1 time)
GBM (1 time)
|
2005 Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.
|
| 13 |
BACKGROUND: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine
(1 time)
|
Neoplasms
(1 time)
|
AUC (1 time)
|
1993 Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
|
| 14 |
BACKGROUND: We have reported that carmustine
(1 time)
|
Medicine
(1 time)
|
PCV (1 time)
|
2005 Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
|
| 15 |
based on a combination regimen with carmustine
(1 time)
|
Brain
(1 time)
|
MTX (1 time)
PB (1 time)
PHT (1 time)
|
1983 Decreased phenytoin level during antineoplastic therapy: a case report.
|
| 16 |
BCNU administered
(1 time)
|
Pathology
(1 time)
|
LPO (1 time)
|
1999 Cytoprotective effects of trimetazidine in carmustine cholestasis.
|
| 17 |
BCNU therapy in R
(1 time)
|
Diagnostic Imaging
(1 time)
|
ADC (1 time)
SI (1 time)
|
2006 Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
|
| 18 |
BCNU were determined and plasma AUC
(1 time)
|
Transplantation
(1 time)
|
HDCT (1 time)
PBPC (1 time)
|
1998 High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
|
| 19 |
BEAM regimen consisting of carmustine
(1 time)
|
Hematology
(1 time)
|
auto-HSCT (1 time)
Mel (1 time)
OS (1 time)
|
2016 Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
|
| 20 |
been reported that the toxicity of carmustine
(1 time)
|
Drug Therapy
(1 time)
|
ALDH1 (1 time)
CEPM (1 time)
CY (1 time)
|
2001 Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.
|
| 21 |
been used in testing other active agents such as carmustine
(1 time)
|
Neoplasms
(1 time)
|
CT (1 time)
MRI (1 time)
SWOG (1 time)
|
1991 Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
|
| 22 |
being treated with carmustine
(1 time)
|
Medicine
(1 time)
|
---
|
1980 Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
|
| 23 |
bendamustine replacing carmustine
(1 time)
|
Hematology
(1 time)
|
ASCT (1 time)
BeEAM (1 time)
CR (1 time)
|
2017 A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
|
| 24 |
benefit for chemotherapy using carmustine
(1 time)
|
Neoplasms
(1 time)
|
Ara-C (1 time)
KPS (1 time)
|
2003 Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
|
| 25 |
beta-hydroxybutyric acid and anticancer agents: carmustine
(1 time)
|
Chemistry
(1 time)
|
GBM (1 time)
MCT1 (1 time)
SLN (1 time)
|
2021 Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture.
|
| 26 |
better than that of carmustine
(1 time)
|
Biochemistry
(1 time)
|
AO/EB (1 time)
AP (1 time)
DAPI (1 time)
|
2013 Synergistic anti-glioma effect of Hydroxygenkwanin and Apigenin in vitro.
|
| 27 |
between anticancer drugs such as carmustine
(1 time)
|
Neurology
(1 time)
|
P-gp (1 time)
PCB (1 time)
VCR (1 time)
|
2000 The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme.
|
| 28 |
between carmustine
(1 time)
|
Antineoplastic Agents
(1 time)
|
CI (1 time)
rhTNF alpha (1 time)
TNF (1 time)
|
1992 A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.
|
| 29 |
between GAT and carmustine
(1 time)
|
Biochemistry
(1 time)
|
CENU (1 time)
|
1988 Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides.
|
| 30 |
bifunctional alkylating agents carmustine
(1 time)
|
Neoplasms
(1 time)
|
---
|
1992 Enhancement of alkylating agent activity in vitro by PD 128763, a potent poly(ADP-ribose) synthetase inhibitor.
|
| 31 |
Bifunctional alkylating agents, such as chlorambucil or carmustine
(1 time)
|
Biochemistry
(1 time)
|
1-meA (1 time)
3-meC (1 time)
ICLs (1 time)
|
2004 Alkylation damage in DNA and RNA--repair mechanisms and medical significance.
|
| 32 |
biodegradable wafers impregnated with carmustine
(1 time)
|
Nervous System Neoplasms
(1 time)
|
VIGILANT (1 time)
|
2017 Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.
|
| 33 |
bleomycin, cisplatin, cyclophosphamide and bischloroethylnitosurea
(1 time)
|
Genetics
(1 time)
|
SCE (1 time)
|
2003 Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
|
| 34 |
blood flow within the middle cerebral artery during 1.3-bis(2-chlorethyl)nitrosurea
(1 time)
|
Radiology
(1 time)
|
---
|
1986 Transcranial Doppler monitoring of blood flow in the middle cerebral artery during angiography and drug perfusion.
|
| 35 |
bone marrow cells for carmustine
(1 time)
|
Antineoplastic Agents
(1 time)
|
CFE (1 time)
CFU-GM (1 time)
|
1994 Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
|
| 36 |
bone marrow transplantation (HDCT/ABMT) with cyclophosphamide, etoposide, and carmustine
(1 time)
|
Neoplasms
(1 time)
|
Dexa-BEAM (1 time)
HDCT/ABMT (1 time)
WHO (1 time)
|
1994 Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
|
| 37 |
border, and chemotherapy with nitrosourea
(1 time)
|
Neurology
(1 time)
|
CT (1 time)
|
2000 Long-term survival in a patient with supratentorial glioblastoma: clinical considerations.
|
| 38 |
both diamide, which is an oxidant of GSH, and 1,3bis(2-chlorethyl)-1-nitrosourea
(1 time)
|
Ophthalmology
(1 time)
|
TM (1 time)
|
1983 Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility.
|
| 39 |
brain tumor cases in the pre-Carmustine
(1 time)
|
Brain
(1 time)
|
FS (1 time)
IOD (1 time)
PS (1 time)
|
2014 Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
|
| 40 |
brain tumors following the administration of cisplatin and carmustine
(1 time)
|
Medicine
(1 time)
|
---
|
1989 Decreased phenytoin levels in patients receiving chemotherapy.
|
| 41 |
brain tumors was correlated with resistance to carmustine
(1 time)
|
Neoplasms
(1 time)
|
---
|
1996 Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
|
| 42 |
breast carcinoma resistant to the common treatment regimens, vindesine, carmustine
(1 time)
|
Neoplasms
(1 time)
|
---
|
1982 [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
|
| 43 |
breathing, and carmustine
(1 time)
|
Neoplasms
(1 time)
|
---
|
1988 Potentiation of rat brain tumor therapy by fluosol and carbogen.
|
| 44 |
Bu instead of carmustine
(1 time)
|
Hematology
(1 time)
|
ASCT (1 time)
Bu (1 time)
PTCLs (1 time)
|
2020 Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
|
| 45 |
Bulk quantities and pharmaceutical preparations of the antineoplastic drugs carmustine
(1 time)
|
Pharmacology
(1 time)
|
PCNU (1 time)
|
1989 Degradation and disposal of some antineoplastic drugs.
|
| 46 |
Busulfan, carmustine
(1 time)
|
Antineoplastic Agents
(1 time)
|
VOD (1 time)
|
1995 High-dose chemotherapy regimens for solid tumors.
|
| 47 |
compounds--1,3-bis(2-chloroethyl)-1-nitrosourea
(1 time)
|
Neurosurgery
(1 time)
|
CCNU (1 time)
|
1982 Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
|
| 48 |
R3L6-BCNU had the highest transfection at a 0.8:1 weight ratio
(1 time)
|
Biochemistry
(1 time)
|
pDNA (1 time)
PLL (1 time)
R3L6 (1 time)
|
2011 Characterization of hydrophobic anti-cancer drug-loaded amphiphilic peptides as a gene carrier.
|
A Search Service for Abbreviation / Long Form